Phase IIINeuropeptide
Compound 61778
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061778
Risk Class
HIGH
Last Audit
Jul 28, 2108
Research Abstract
Neuropeptide candidate engineered for oncology adjuvant initiatives with automated dossier coverage.
Compound 61778 is a neuropeptide asset inside neuropeptide innovation track initiatives, optimized for oncology adjuvant and inflammation control.
The dossier currently sits in phase iii with a high risk rating, meaning it is restricted to black-box teams with hardened compliance.
Supply records cite CAS AUTO-061778 with updates logged 2108-07-28.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Oncology adjuvantInflammation control
Nomenclature
CX-61778Neuropeptide Program 61778
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061778
- [2] Operations Pulse • Neuropeptide innovation track
- [3] Risk Governance Ledger • HIGH clearance for COMPOUND-61778